Novartis scraps Fabhalta study in lupus nephritis

Trial StartFabhaltaNegative

AI Analysis

Summary

Novartis terminated a mid-stage trial of Fabhalta (iptacopan) in lupus nephritis, citing 'strategic considerations,' according to a federal clinical trials database. Fabhalta is a key part of Novartis' portfolio.

Clinical Trial Data

Phase

Phase_2

Outcome Details

Novartis terminated a mid-stage trial of Fabhalta in lupus nephritis, citing 'strategic considerations,' per a federal clinical trials database.

Importance:4/10

Sentiment:

-0.30

trial_terminationlupus_nephritisiptacopanpipelinestrategic_decision

Related Companies

$NVS

Read the original article

Published by Endpoints News on October 16, 2026 3:32 PM

Read Original